Study Exclusion reasons Remarks Reference(s)
Ahn, 2020 -

Ahn J. Korean Med. Sci. 2020; 35:e149 10.3346/jkms.2020.35.e149

 
Shen, 2020 -

Shen C JAMA 2020 Mar 27;323(16):1582-1589. 10.1001/jama.2020.4783

 
O'Brien (Part A: uninfected household contacts), 2021 randomized controlled trial < Study carried out before the release of the omicron variant >

O'Brien MP et al. medrxiv;2021.06.14.21258569v1 10.1101/2021.06.14.21258569

O'Brien MP et al. New England Journal of Medicine 10.1056/NEJMoa2109682

O?Brien MP et al. medRxiv 10.1101/2021.06.14.21258567

 
O'Brien (Part B: recently infected asymptomatic patients), 2021 randomized controlled trial

O'Brien MP et al. medrxiv;2021.06.14.21258569v1 10.1101/2021.06.14.21258569

 
Ye, 2020 - no control group

Ye J. Med. Virol. 2020; : 10.1002/jmv.25882

 
Zhang, 2020 - no control group

Zhang Chest 2020; : 10.1016/j.chest.2020.03.039

 
Zhang, 2020 - no control group

Zhang L Aging (Albany NY) 2020 Apr 22;12(8):6536-6542. 10.18632/aging.103102

 
CT-P59 1.2, 2020 randomized controlled trial no clinically relevant endpoint preliminary unpublished results extracted from the EMA review document. < Study carried out before the release of the omicron variant >  
Bargay-Lleonart, 2022 randomized controlled trial no clinically relevant endpoint The trial was terminated early due to the impossibility of recruitment due to the pandemic.

Bargay-Lleonart J J Clin Med 2022 May 27;11(11):3039. 10.3390/jcm11113039

 
Dai W, 2020 retrospective cohort other inadequate statistical analysis

Wei Dai, Jian Wu, Tianfu Li, Jiawei Shen, Rongrong Pang, Bangshun He, Tao Luo, Yanju Guo, Yang Yang, Jun Zhao, Mingchao Zhang, Na Li, Ying Han, Qiuyue Wu, Weiwei Li, Xinyi Xia BMC Cardiovascular Diabetology

 
Isa, 2021 randomized controlled trial other Phase I: multiple-dose administration of REGEN-COV.

Isa F et al. medRxiv 10.1101/2021.11.10.21265889